Chromatin remodeling and leukemia: New therapeutic paradigms

Blood

Volumn 94, Issue 2, 1999, Pages 417-428

  Redner, Robert L ^a   Wang, Jianxiang ^b   Liu, Johnson M ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 CARBOXYCINNAMIC ACID BISHYDROXAMIDE; ARSENIC TRIOXIDE; ARYLBUTYRIC ACID DERIVATIVE; AZACITIDINE; BUTYRIC ACID; BUTYRIC ACID DERIVATIVE; DNA; DNA TOPOISOMERASE INHIBITOR; ENZYME INHIBITOR; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HYBRID PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; TRAPOXIN; TRIBUTYRIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

ACETYLATION; CHROMATIN; DNA HISTONE INTERACTION; DRUG POTENTIATION; HUMAN; LEUKEMIA; MODEL; NONHUMAN; NUCLEOSOME; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW;

EID: 0033566302     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.2.417.414k49_417_428     Document Type: Review

References (150)

1. Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ: Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389:251, 1997
2. Rhodes D: Chromatin structure. The nucleosome core all wrapped up. Nature 389:233, 1997
3. Olins AL, Olins DE: Spheroid chromatin units (v bodies). Science 183:330, 1974
4. Finch JT, Klug A: Solenoidal model for superstructure in chromatin. Proc Natl Acad Sci USA 73:1897, 1976
5. Cao H, Widlund HR, Simonsson T, Kubista M: TGGA repeats impair nucleosome formation. J Mol Biol 281:253, 1998
6. Schild-Poulter C, Sassone-Corsi P, Granger-Schnarr M, Schnarr M: Nucleosome assembly on the human c-fos promoter interferes with transcription factor binding. Nucleic Acids Res 24:4751, 1996
7. Studitsky VM, Clark DJ, Felsenfeld G: Overcoming a nucleosomal barrier to transcription. Cell 83:19, 1995
8. Geraghty DS, Sucic HB, Chen J, Pederson DS: Evidence that partial unwrapping of DNA from nucleosomes facilitates the binding of heat shock factor following DNA replication in yeast. J Biol Chem 273:20463, 1998
9. Tsukiyama T, Wu C: Chromatin remodeling and transcription. Curr Opin Genet Dev 7:182, 1997
10. Bartsch J, Truss M, Bode J, Beato M: Moderate increase in histone acetylation activates the mouse mammary tumor virus promoter and remodels its nucleosome structure. Proc Natl Acad Sci USA 93:10741, 1996
11. Grunstein M: Histone acetylation in chromatin structure and transcription. Nature 389:349, 1997
12. Hebbes TR, Thorne AW, Crane-Robinson C: A direct link between core histone acetylation and transcriptionally active chromatin. EMBO J 7:1395, 1988
13. Tse C, Sera T, Wolffe AP, Hansen JC: Disruption of higher-order folding by core histone acetylation dramatically enhances transcription of nucleosomal arrays by RNA polymerase III. Mol Cell Biol 18:4629, 1998
14. Vettese-Dadey M, Grant PA, Hebbes TR, Crane-Robinson C, Allis CD, Workman JL: Acetylation of histone H4 plays a primary role in enhancing transcription factor binding to nucleosomal DNA in vitro. EMBO J 15:2508, 1996
15. Walia H, Chen HY, Sun JM, Holth LT, Davie JR: Histone acetylation is required to maintain the unfolded nucleosome structure associated with transcribing DNA. J Biol Chem 273:14516, 1998
16. Ura K, Kurumizaka H, Dimitrov S, Almouzni G, Wolffe AP: Histone acetylation: Influence on transcription, nucleosome mobility and positioning, and linker histone-dependent transcriptional repression. EMBO J 16:2096, 1997
17. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A: Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393: 386, 1998
18. Tremethick DJ, Hyman L: High mobility group protein 14 and 17 can prevent the close packing of nucleosomes by increasing the strength of protein contacts in the linker DNA. J Biol Chem 271: 12009, 1996
19. Postnikov YV, Herrera JE, Hock R, Scheer U, Bustin M: Clusters of nucleosomes containing chromosomal protein HMG-17 in chromatin. J Mol Biol 274:454, 1997
20. Glass CK, Rose DW, Rosenfeld MG: Nuclear receptor coactivators. Curr Opin Cell Biol 9:222, 1997
21. Utley RT, Ikeda K, Grant PA, Cote J, Steger DJ, Eberharter A, John S, Workman JL: Transcriptional activators direct histone acetyltransferase complexes to nucleosomes. Nature 394:498, 1998
22. Evans R: The steroid and thyroid hormone receptor superfamily. Nature 240:889, 1988
23. Yu VC, Delsert C, Andersen B, Holloway JM, Devary OV, Naar AM, Kim SY, Boutin JM, Glass CK, Rosenfeld MG: RXR beta: A coregulator that enhances binding of retinoic acid, thyroid hormone, and vitamin D receptors to their cognate response elements. Cell 67:1251, 1991
24. Umesono K, Murakami KK, Thompson CC, Evans RM: Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors. Cell 65:1255, 1991
25. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR: AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84:321, 1996
26. Yang N, Schule R, Mangelsdorf DJ, Evans RM: Characterization of DNA binding and retinoic acid binding properties of retinoic acid receptor. Proc Natl Acad Sci USA 9:3559, 1991
27. Horlein AJ, Naar AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, Ryan A, Kamei Y, Soderstrom M, Glass CK, Rosenfeld MG: Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377:397, 1995
28. Kurokawa R, Soderstrom M, Horlein A, Halachmi S, Brown M, Rosenfeld MG, Glass CK: Polarity-specific activities of retinoic acid receptors determined by a co-repressor. Nature 377:451, 1995
29. Chen JD, Evans RM: A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377:454, 1995
30. Chen JD, Umesono K, Evans RM: SMRT isoforms mediate repression and anti-repression of nuclear receptor heterodimers. Proc Natl Acad Sci USA 93:7567, 1996
31. Alland L, Muhle R, Hou H Jr, Potes J, Chin L, Schreiber-Agus N, DePinho RA: Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature 387:49, 1997
32. Laherty CD, Yang WM, Sun JM, Davie JR, Seto E, Eisenman RN: Histone deacetylases associated with the mSin3 corepressor mediate Mad transcriptional repression. Cell 89:349, 1997
33. Heinzel T, Lavinsky RM, Mullen TM, Soderstrom M, Laherty CD, Torchia J, Yang WM, Brard G, Ngo SD, Davie JR, Seto E, Eisenman RN, Rose DW, Glass CK, Rosenfeld MG: A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 387:43, 1997
34. Hassig CA, Tong JK, Fleischer TC, Owa T, Grable PG, Ayer DE, Schreiber SL: A role for histone deacetylase activity in HDAC1-mediated transcriptional repression. Proc Nad Acad Sci USA 95:3519, 1998
35. Ayer DE, Lawrence QA, Eisenman RN: Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3. Cell 80:767, 1995
36. Harper SE, Qiu Y, Sharp PA: Sin3 corepressor function in Myc-induced transcription and transformation. Proc Natl Acad Sci USA 93:8536, 1996
37. Wang JX, Hoshino T, Redner RL, Kajigaya S, Liu JM: ETO, fusion partner in t(8-21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci USA 95:10860, 1998
38. Gelmetti V, Zhang JS, Fanelli M, Minucci S, Pelicci PG, Lazar MA: Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 18:7185, 1998
39. Lutterbach B, Westendorf JJ, Linggi B, Patten A, Moniwa M, Davie JR, Huynh KD, Bardwell VJ, Lavinsky RM, Rosenfeld MG, Glass C, Seto E, Hiebert SW: ETO, a target of t(8-21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol 18:7176, 1998
40. Driscoll JE, Seachord CL, Lupisella JA, Darveau RP, Reczek PR: Ligand-induced conformational changes in the human retinoic acid receptor detected using monoclonal antibodies. J Biol Chem 271:22969, 1996
41. Heery DM, Kalkhoven E, Hoare S, Parker MG: A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387:733, 1997
42. Lin BC, Hong SH, Krig S, Yoh SM, Privalsky ML: A conformational switch in nuclear hormone receptors is involved in coupling hormone binding to corepressor release. Mol Cell Biol 7:6131, 1997
43. Jenster G, Spencer TE, Burcin MM, Tsai SY, Tsai MJ, O'Malley BW: Steroid receptor induction of gene transcription: A two-step model. Proc Natl Acad Sci USA 94:7879, 1997
44. Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK, Rosenfeld MG: The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 387:677, 1997
45. Blanco JC, Minucci S, Lu J, Yang XJ, Walker KK, Chen H, Evans RM, Nakatani Y, Ozato K: The histone acetylase PCAF is a nuclear receptor coactivalor. Genes Dev 12:1638, 1998
46. Beato M, Candau R, Chavez S, Mows C, Truss M: Interaction of steroid hormone receptors with transcription factors involves chromatin remodelling. J Steroid Biochem Mol Biol 56:47, 1996
47. McKenna NJ, Nawaz Z, Tsai SY, Tsai MJ, O'Malley BW: Distinct steady-state nuclear receptor coregulator complexes exist in vivo. Proc Natl Acad Sci USA 95:11697, 1998
48. Li H, Gomes PJ, Chen JD: RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. Proc Natl Acad Sci USA 94:8479, 1997
49. Carapeti M, Aguiar RC, Goldman JM, Cross NC: A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. Blood 91:3127, 1998
50. Eckner R: p300 and CBP as transcriptional regulators and targets of oncogenic events. Biol Chem 377:685, 1996
51. Martinez-Balbas MA, Bannister AJ, Martin K, Haus-Seuffert P, Meisterernst M, Kouzarides T: The acetyltransferase activity of CBP stimulates transcription. EMBOJ 17:2886, 1998
52. Giles RH, Peters D, Breuning MH: Conjunction dysfunction-CBP/p300 in human disease. Trends Genet 14:178, 1998
53. Imhof A, Yang XJ, Ogryzko VV, Nakatani Y, Wolffe AP, Ge H: Acetylation of general transcription factors by histone acetyltransferases. Curr Biol 7:689, 1997
54. Spencer TE, Jenster G, Burcin MM, Allis CD, Zhou J, Mizzen CA, McKenna NJ, Onate SA, Tsai SY, Tsai MJ, O'Malley BW: Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 389:194, 1997
55. Razin A, Cedar H: DNA methylation and gene expression. Microbiol Rev 55:451, 1991
56. Davey C, Pennings S, Allan J: CpG methylation remodels chromatin structure in vitro. J Mol Biol 267:276, 1997
57. Nan X, Campoy FJ, Bird A: MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 88:471, 1997
58. Jones PA: Altering gene expression with 5-azacytidine. Cell 40:485, 1985
59. Burns LG, Peterson CL: The yeast SW1-SNF complex facilitates binding of a transcriptional activator to nucleosomal sites in vivo. Mol Cell Biol 17:4811, 1997
60. Cote J, Peterson CL, Workman JL: Perturbation of nucleosome core structure by the SWI/SNF complex persists after its detachment, enhancing subsequent transcription factor binding. Proc Natl Acad Sci USA 95:4947, 1998
61. Logic C, Peterson CL: Catalytic activity of the yeast SWI/SNF complex on reconstituted nucleosome arrays. EMBO J 16:6772, 1997
62. Schnitzler G, Sif S, Kingston RE: Human SWI/SNF interconverts a nucleosome between its base state and a stable remodeled state. Cell 94:17, 1998
63. Ryan MP, Jones R, Morse RH: SWI-SNF complex participation in transcriptional activation at a step subsequent to activator binding. Mol Cell Biol 18:1774, 1998
64. Mizuguchi G, Tsukiyama T, Wisniewski J, Wu C: Role of nucleosome remodeling factor NURF in transcriptional activation of chromatin. Mol Cell 1:141, 1997
65. Cairns BR, Lorch Y, Li Y, Zhang M, Lacomis L, Erdjument-Bromage H, Tempst P, Du J, Laurent B, Kornberg RD: RSC, an essential, abundant chromatin-remodeling complex. Cell 87:1249, 1996
66. Lorch Y, Cairns BR, Zhang M, Kornberg RD: Activated RSC-nucleosome complex and persistently altered form of the nucleosome. Cell 94:29, 1998
67. Ito T, Bulger M, Pazin MJ, Kobayashi R, Kadonaga JT: ACF, an ISWI-containing and ATP-utilizing chromatin assembly and remodeling factor. Cell 90:145, 1997
68. Auble DT, Wang DY, Post KW, Hahn S: Molecular analysis of the SNF2/SWI2 protein family member Mot1, an ATP-driven enzyme that dissociates TATA-binding protein from DNA. Mol Cell Biol 17:4842, 1997
69. Wang W, Cote J, Xue Y, Zhou S, Khavari PA, Biggar SR, Muchardt C, Kalpana GV, Goff SP, Yaniv M, Workman JL, Crabtree GR: Purification and biochemical heterogeneity of the mammalian SWI-SNF complex. EMBO J 15:5370, 1996
70. Dallas PB, Cheney IW, Liao DW, Bowrin V, Byam W, Pacchione S, Kobayashi R, Yaciuk P, Moran E: p300/CREB binding protein-related protein p270 is a component of mammalian SWI/SNF complexes. Mol Cell Biol 18:3596, 1998
71. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ, Wang ZY: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567, 1988
72. Warrell RJ, Frankel SR, Miller WJ, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, Gabrilove J, Gordon MS, Dmitrovsky E: Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 324:1385, 1991
73. Warrell R Jr, de The H, Wang ZY, Degos L: Acute promyelocytic leukemia. N Engl J Med 329:177, 1993
74. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH: All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337:1021, 1997
75. Tsai S, Collins SJ: A dominant negative retinoic acid receptor blocks neutrophil differentiation at the promyelocyte stage. Proc Natl Acad Sci USA 90:7153, 1993
76. Tsai S, Bartelmez S, Heyman R, Damm K, Evans R, Collins S: A mutated retinoic acid receptor-alpha exhibiting dominant-negative activity alters the lineage evelopment of a multipotent hematopoietic cell line. Genes Dev 6:2258, 1992
77. Borrow J, Goddard AD, Sheer D, Solomon E: Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 249:1577, 1990
78. Kakizuka A, Miller WJ, Umesono K, Warrell RJ, Frankel SR, Murty VV, Dmitrovsky E, Evans RM: Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66:663, 1991
79. de The H, Chomienne C, Lanotte M, Degos L, Dejean A: The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 347:558, 1990
80. Chen Z, Brand NJ, Chen A, Chen SJ, Tong JH, Wang ZY, Waxman S, Zelent A: Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J 12:1161, 1993
81. Redner RL, Rush EA, Faas S, Rudert WA, Corey SJ: The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood 87:882, 1996
82. Wells RA, Hummel JL, De Koven A, Zipursky A, Kirby M, Dube I, Kamel-Reid S: A new variant translocation in acute promyelocytic leukaemia: Molecular characterization and clinical correlation. Leukemia 10:735, 1996
83. Licht JD, Chomienne C, Goy A, Chen A, Scott AA, Head DR, Michaux JL, Wu Y, DeBlasio A, Miller WH, Zelenetz AD, Wilman CL, Chen Z, Chen S-J, Zelent A, Macintyre E, Veil A, Cortes J, Kantarjian H, Waxman S: Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 85:1083, 1995
84. Licht JD, Shaknovitch R, English MA, Melnick A, Li J-Y, Reddy JC, Dong S, Chen S-J, Zelent A, Waxman S: Reduced and altered DNA-binding and transcriptional properties of the PLZF-retinoic acid receptor-α chimera generated in t(11;17)-associated acute promyelocytic leukemia. Oncogene 12:323, 1996
85. de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A: The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66:675, 1991
86. Grignani F, Dematteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seiser C, Grignani F, Lazar MA, Minucci S, Pelicci PG: Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391:815, 1998
87. Guidez F, Ivins S, Zhu J, Soderstrom M, Waxman S, Zelent A: Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML-and PLZF-RAR-alpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 91:2634, 1998
88. He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A, Pandolfi PP: Distinct interactions of PML-RAR-alpha and PLZF-RAR-alpha with co-repressors determine differential responses to RA in APL. Nat Genet 18:126, 1998
89. Lin RJ, Nagy L, Inoue S, Shao WL, Miller WH, Evans RM: Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391:811, 1998
90. Redner RL, Corey SJ, Rush EA: Differentiation of t(5;17) variant acute promyelocytic leukemic blasts by all-trans retinoic acid. Leukemia 11:1014, 1997
91. Ahmad KF, Engel CK, Prive GG: Crystal structure of the BTB domain from PLZF. Proc Natl Acad Sci USA 95:12123, 1998
92. Li X, Lopez-Guisa JM, Ninan N, Weiner EJ, Rauscher F3, Marmorstein R: Overexpression, purification, characterization, and crystallization of the BTB/POZ domain from the PLZF oncoprotein. J Biol Chem 272:27324, 1997
93. Hong SH, David G, Wong CW, Dejean A, Privalsky ML: SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor alpha (RARalpha) and PLZF-RARalpha oncoproteins associated with acute promyelocytic leukemia. Proc Natl Acad Sci USA 94:9028, 1997
94. David G, Alland L, Hong SH, Wong CW, DePinho RA, Dejean A: Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene 16:2549, 1998
95. Dhordain P, Albagli O, Lin RJ, Ansieau S, Quief S, Leutz A, Kerckaert JP, Evans RM, Leprince D: Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein. Proc Natl Acad Sci USA 94:10762, 1997
96. Guidez F, Huang W, Tong JH, Dubois C, Balitrand N, Waxman S, Michaux JL, Martiat P, Degos L, Chen Z, Chomienne C: Poor response to all-trans retinoic acid therapy in a t(11;17) PLZF/RAR alpha patient. Leukemia 8:312, 1994
97. Hiebert SW, Downing JR, Lenny N, Meyers S: Transcriptional regulation by the t(8;21) fusion protein, AML-1/ETO. Curr Top Microbiol Immunol 211:253, 1996
98. Bloomfield CD, Shuma C, Regal L, Philip PP, Hossfeld DK, Hagemeijer AM, Garson OM, Peterson BA, Sakurai M, Alimena G, Berger R, Rowley JD, Ruutu T, Mitelman F, Dewald GW, Swansbury J: Long-term survival of patients with acute myeloid leukemia: A third follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer 80:2191, 1997
99. Bennett JM, Young ML, Andersen JW, Cassileth PA, Tallman MS, Paietta E, Wiernik PH, Rowe JM: Long-term survival in acute myeloid leukemia: The Eastern Cooperative Oncology Group experience. Cancer 80:2205, 1997
100. Meyers S, Downing JR, Hiebert SW: Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: The runt homology domain is required for DNA binding and protein-protein interactions. Mol Cell Biol 13:6336, 1993
101. Kitabayashi I, Yokoyama A, Shimizu K, Ohki M: Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation. EMBO J 17:2994, 1998
102. Frank R, Zhang J, Uchida H, Meyers S, Hiebert SW, Nimer SD: The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. Oncogene 11:2667, 1995
103. Yergeau DA, Hetherington CJ, Wang Q, Zhang P, Sharpe AH, Binder M, Marin-Padilla M, Tenen DG, Speck NA, Zhang DE: Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet 15:303, 1997
104. Lenny N, Meyers S, Hiebert SW: Functional domains of the t(8;21) fusion protein, AML-1/ETO. Oncogene 11:1761, 1995
105. + hematopoietic progenitors: Implications for t(8;21) leukemogenesis and monitoring residual disease. Blood 88:1813, 1996
106. Wang J, Wang M, Liu JM: Transformation properties of the ETO gene, fusion partner in t(8;21) leukemias. Cancer Res 57:2951, 1997
107. Downing JR, Look AT: MLL fusion genes in the 11q23 acute leukemias. Cancer Treat Res 84:73, 1996
108. Cimino G, Rapanotti MC, Sprovieri T, Elia L: ALL1 gene alterations in acute leukemia: Biological and clinical aspects. Haematologica 83:350, 1998
109. Janssen JW, Ludwig WD, Borkhardt A, Spadinger U, Rieder H, Fonatsch C, Hossfeld DK, Harbott J, Schulz AS, Repp R, Sykkora KW, Hoelzer D, Bartram CR: Pre-pre-B acute lymphoblastic leukemia: High frequency of alternatively spliced ALLI-AF4 transcripts and absence of minimal residual disease during complete remission. Blood 84:3835, 1994
110. Caligiuri MA, Strout MP, Schichman SA, Mrozek K, Arthur DC, Herzig GP, Baer MR, Schiffer CA, Heinonen K, Knuutila S, Nousiainen T, Ruutu T, Block AW, Schulman P, Pedersen-Bjergaard J, Croce CM, Bloomfield CD: Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res 56:1418, 1996
111. Rasio D, Schichman SA, Negrini M, Canaani E, Croce CM: Complete exon structure of the ALL1 gene. Cancer Res 56:1766, 1996
112. Djabali M, Selleri L, Parry P, Bower M, Young BD, Evans GA: A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias. Nat Genet 2:113, 1992
113. Ma Q, Alder H, Nelson KK, Chatterjee D, Gu Y, Nakamura T, Canaani E, Croce CM, Siracusa LD, Buchberg AM: Analysis of the murine All-1 gene reveals conserved domains with human ALL-1 and identities a motif shared with DNA methyltransferases. Proc Natl Acad Sci USA 90:6350, 1993
114. Parry P, Djabali M, Bower M, Khristich J, Waterman M, Gibbons B, Young BD, Evans G: Structure and expression of the human trithorax-like gene 1 involved in acute leukemias. Proc Natl Acad Sci USA 90:4738, 1993
115. Tkachuk DC, Kohler S, Cleary ML: Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell 71:691, 1992
116. Breen TR, Harte PJ: Molecular characterization of the trithorax gene, a positive regulator of homeotic gene expression in Drosophila. Mech Dev 35:113, 1991
117. Breen TR, Harte PJ: Trithorax regulates multiple homeotic genes in the bithorax and Antennapedia complexes and exerts different tissue-specific, parasegment-specific and promoter-specific effects on each. Development 117:119, 1993
118. Mazo AM, Huang DH, Mozer BA, Dawid IB: The trithorax gene, a trans-acting regulator of the bithorax complex in Drosophila, encodes a protein with zinc-binding domains. Proc Natl Acad Sci USA 87:2112, 1990
119. Orlando V, Jane EP, Chinwalla V, Harte PJ, Paro R: Binding of trithorax and polycomb proteins to the bithorax complex - Dynamic changes during early drosophila embryogenesis. EMBO J 17:5141, 1998
120. Yu BD, Hanson RD, Hess JL, Horning SE, Korsmeyer SJ: MLL, a mammalian trithorax-group gene, functions as a transcriptional maintenance factor in morphogenesis. Proc Natl Acad Sci USA 95:10632, 1998
121. Rozenblatt-Rosen O, Rozovskaia T, Burakov D, Sedkov Y, Tillib S, Blechman J, Nakamura T, Croce CM, Mazo A, Canaani E: The C-terminal SET domains of ALL-1 and Trithorax interact with the INI1 and SNR1 proteins, components of the SWI/SNF complex. Proc Natl Acad Sci USA 95:4152, 1998
122. Zeleznik-Le NJ, Harden AM, Rowley JD: 11q23 translocations split the "AT-hook" cruciform DNA-binding region and the transcriptional repression domain from the activation domain of the mixed-lineage leukemia (MLL) gene. Proc Natl Acad Sci USA 91:10610, 1994
123. Nakamura T, Alder H, Gu Y, Prasad R, Canaani O, Kamada N, Gale RP, Lange B, Crist WM, Nowell PC, Croce CM, Canaani E: Genes on chromosomes 4, 9, and 19 involved in 11q23 abnormalities in acute leukemia share sequence homology and/or common motifs. Proc Natl Acad Sci USA 90:4631, 1993
124. Cairns BR, Henry NL, Kornberg RD: TFG/TAF30/ANC1, a component of the yeast SWI/SNF complex that is similar to the leukemogenic proteins ENL and AF-9. Mol Cell Biol 16:3308, 1996
125. Sobulo OM, Borrow J, Tomek R, Reshmi S, Harden A, Schlegelberger B, Housman D, Doggett NA, Rowley JD, Zeleznik-Le NJ: MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc Natl Acad Sci USA 94:8732, 1997
126. Rowley JD, Reshmi S, Sobulo O, Musvee T, Anastasi J, Raimondi S, Schneider NR, Barredo JC, Cantu ES, Schlegelberger B, Behm F, Doggett NA, Borrow J, Zeleznik-Le N: All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood 90:535, 1997
127. Taki T, Sako M, Tsuchida M, Hayashi Y: The t(11;16)(q23;p13) translocation in myelodysplastic syndrome fuses the MLL gene to the CBP gene. Blood 89:3945, 1997
128. Ida K, Kitabayashi I, Taki T, Taniwaki M, Noro K, Yamamoto M, Ohki M, Hayashi Y: Adenoviral E1A-associated protein p300 is involved in acute myeloid leukemia with t(11;22)(q23;q13). Blood 90:4699,1997
129. Borrow J, Stanton V Jr, Andresen JM, Becher R, Behm FG, Chaganti RS, Civin CI, Disteche C, Dube I, Frischauf AM, Horsman D, Mitelman F, Volinia S, Watmore AE, Housman DE: The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltrans ferase to the CREB-binding protein. Nat Genet 14:33, 1996
130. Candido EP, Reeves R, Davie JR: Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 14:105, 1978
131. Boffa LC, Vidali G, Mann RS, Allfrey VG: Suppression of histone deacetylation in vivo and in vitro by sodium butyrate. J Biol Chem 253:3364, 1978
132. Vidali G, Boffa LC, Bradbury EM, Allfrey VG: Butyrate suppression of histone deacetylation leads to accumulation of multiacetylated forms of histones H3 and H4 and increased DNase I sensitivity of the associated DNA sequences. Proc Natl Acad Sci USA 75:2239, 1978
133. Elder DJ, Morgan P, Kelly DJ: Anaerobic degradation of trans-cinnamate and omega-phenylalkane carboxylic acids by the photosynthetic bacterium Rhodopseudomonas palustris: Evidence for a beta-oxidation mechanism. Arch Microbiol 157:148, 1992
134. Samid D, Hudgins WR, Shack S, Liu L, Prasanna P, Myers CE: Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers. Adv Exp Med Biol 501, 1997
135. Yoshida M, Beppu T: Reversible arrest of proliferation of rat 3Y1 fibroblasts in both the G1 and G2 phases by trichostatin A. Exp Cell Res 177:122, 1988
136. Yoshida M, Kijima M, Akita M, Beppu T: Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265:17174, 1990
137. Itazaki H, Nagashima K, Sugita K, Yoshida H, Kawamura Y, Yasuda Y, Matsumoto K, Ishii K, Uotani N, Nakai H, Terui A, Yoshimatsu S, Ikanishi Y, Nakagawa Y: Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents. J Antibiot 43:1524, 1990
138. Kijima M, Yoshida M, Sugita K, Horinouchi S, Beppu T: Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem 268:22429, 1993
139. Yoshida M, Horinouchi S, Beppu T: Trichostatin A and trapoxin: Novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays 17:423, 1995
140. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, Civoli F, Breslow R, Rifkind RA, Marks PA: Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA 93:5705, 1996
141. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, Marks PA: A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 95:3003, 1998
142. Newmark HL, Young CW: Butyrate and phenylacetate as differentiating agents: practical problems and opportunities. J Cell Biochem 22:247, 1995 (suppl 1)
143. Yoshida M, Nomura S, Beppu T: Effects of trichostatins on differentiation of marine erythroleukemia cells. Cancer Res 47:3688, 1987
144. Van Lint C, Emiliani S, Verdin E: The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Exp 5:245, 1996
145. Jansen JH, de Ridder MC, Geertsma WMC, Erpelinck CAJ, Smit B, Slater R, vd Reijden BA, Greef GE, Sonneveld P, Lowenberg B: Complete remission of t(11;17) positive acute promyelocytic leukemia by all-trans retinoic acid and G-CSF. Blood 92:402a, 1998 (abstr, suppl 1)
146. Ding W, Li YP, Nobile LM, Grills G, Carrera I, Paietta E, Tallman M, Wiernik PH, Gallagher RE: Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARα fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy. Blood 92:1172, 1998
147. Warrell RP, He LZ, Richon V, Calleja E, Pandolfi PP: Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Nat Cancer Inst 90:1621, 1998
148. Wang JX, Saunthararajah Y, Redner RL, Liv JM: Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res (in press)
149. Novogrodsky A, Dvir A, Ravid A, Shkolnik T, Stenzel KH, Rubin AL, Zaizov R: Effect of polar organic compounds on leukemic cells. Butyrate-induced partial remission of acute myelogenous leukemia in a child. Cancer 51:9, 1983
150. Mizuno S, Tokunaga Y, Maeda M, Inaba S, Miyamoto T, Akashi K, Godno H, Niho Y: Inhibitor of histone deacetylase upregulates B7 molecules in acute myelogenous leukemia. Blood 92:616a, 1998 (abstr, suppl 1)